The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Expansion Is Expected For The Small Molecule Targeted Therapy Market Over The Forecast Period?
The small molecule targeted therapy market has demonstrated robust expansion over recent years. Forecasts indicate its value will increase from $77.29 billion in 2025 to $84.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.5%. This market’s past growth is attributable to progress in molecular biology research, a growing incidence of chronic diseases, the expansion of pharmaceutical R&D efforts, regulatory approval of targeted therapies, and improvements in drug screening methodologies.
The small molecule targeted therapy market is anticipated to experience substantial expansion in the coming years. Projections indicate it will reach $120.64 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This projected growth is fueled by factors such as the increasing call for personalized medicine, greater incorporation of genomics in drug creation, the broadening application of targeted therapies beyond cancer, a heightened emphasis on drug design that prioritizes safety, and greater investment in precision treatments. Key developments expected during this period involve the expanding development of drugs tailored to specific targets, a rise in the application of therapies that modulate pathways, increased uptake of oral small molecule treatments, a sharper focus on molecular targets specific to diseases, and the wider use of combination small molecule regimens.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28332&type=smp
What Key Growth Drivers Are Influencing The Small Molecule Targeted Therapy Market?
The increasing focus on personalized medicine is expected to propel the growth of the small molecule targeted therapy market going forward. Personalized medicine refers to a healthcare approach that tailors prevention, diagnosis, and treatment to an individual’s genetic, environmental, and lifestyle factors. The expansion of personalized medicine is driven by advances in genomics, allowing a deeper understanding of individual genetic variations and enabling more precise, targeted treatments that improve patient outcomes and reduce trial-and-error in therapies. Small molecule targeted therapy enables personalized medicine by selectively targeting a patient’s specific molecular or genetic disease profile, improving treatment efficacy and reducing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the growing emphasis on personalized medicine is driving the growth of the small molecule targeted therapy market.
Which Segment Groups Define The Small Molecule Targeted Therapy Market Landscape?
The small molecule targeted therapy market covered in this report is segmented –
1) By Type Of Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Drug Class: Monoclonal Antibodies, Small Molecule Inhibitors, Combination Therapies
3) By Mechanism Of Action: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (Ahr) Modulators, Cell Cycle Inhibitors
4) By Disease Indication: Cancer, Autoimmune Diseases, Infectious Diseases
5) By Route Of Administration: Oral, Intravenous, Subcutaneous
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-microtubule Agents
2) By Targeted Therapy: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (AhR) Modulators
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies
What Trends Are Shaping The Small Molecule Targeted Therapy Market Structure?
Major companies operating within the small molecule targeted therapy market are prioritizing the creation of innovative solutions, such as oral small molecules, to improve targeted delivery, boost patient compliance, and address specific molecular pathways in oncology and other chronic conditions. An oral small molecule is characterized as a low-molecular-weight drug that can be consumed by mouth and is designed for easy cellular entry to precisely target disease-related proteins or pathways. For example, in June 2025, Kura Oncology Inc., a US-based biotech company, secured FDA approval for a New Drug Application (NDA) for ziftomenib. This approval is for its use as a treatment for adult patients with relapsed or refractory acute myeloid leukemia (AML) presenting nucleophosmin 1 (NPM1) mutations. This oral targeted therapy is specifically crafted for adult patients with relapsed or refractory AML carrying NPM1 mutations, thereby addressing a crucial unmet medical need. It exhibits a favorable safety profile and has shown promising efficacy, including significant complete remission rates observed in clinical trials. By selectively inhibiting the menin-KMT2A interaction, ziftomenib disrupts leukemic cell growth and supports new treatment approaches for this difficult-to-treat AML subtype.
Which Companies Are Influencing The Small Molecule Targeted Therapy Market?
Major companies operating in the small molecule targeted therapy market are F. Hoffmann-La Roche AG (Roche), Merck KGaA, Pfizer Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, Blueprint Medicines Corporation, Kura Oncology Inc., G1 Therapeutics Inc., Ascentage Pharma Group International Inc., Rgenta Therapeutics Inc., Verastem Inc.
Access The Complete Small Molecule Targeted Therapy Market Report:
Which Region Contributes The Most To The Small Molecule Targeted Therapy Market?
North America was the largest region in the small molecule targeted therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Small Molecule Targeted Therapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=28332&type=smp
Browse Through More Reports Similar to the Global Small Molecule Targeted Therapy Market 2026, By The Business Research Company
Small Molecule Drug Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report
Targeted Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Rna Targeting Small Molecules Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model